These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 22551785)
1. A phase II trial of intrapatient dose-escalated sorafenib in patients with metastatic renal cell carcinoma. Amato R; Zhai J; Willis J; Saxena S; DeFoe M Clin Genitourin Cancer; 2012 Sep; 10(3):153-8. PubMed ID: 22551785 [TBL] [Abstract][Full Text] [Related]
2. Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment. Mancuso A; Di Paola ED; Leone A; Catalano A; CalabrĂ² F; Cerbone L; Zivi A; Messina C; Alonso S; Vigna L; Caristo R; Sternberg CN BJU Int; 2012 Jan; 109(2):200-6. PubMed ID: 22212284 [TBL] [Abstract][Full Text] [Related]
3. Overall survival and good tolerability of long-term use of sorafenib after cytokine treatment: final results of a phase II trial of sorafenib in Japanese patients with metastatic renal cell carcinoma. Naito S; Tsukamoto T; Murai M; Fukino K; Akaza H BJU Int; 2011 Dec; 108(11):1813-9. PubMed ID: 21481133 [TBL] [Abstract][Full Text] [Related]
4. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Akaza H; Tsukamoto T; Murai M; Nakajima K; Naito S Jpn J Clin Oncol; 2007 Oct; 37(10):755-62. PubMed ID: 17951335 [TBL] [Abstract][Full Text] [Related]
5. Sorafenib for the treatment of advanced renal cell carcinoma. Kane RC; Farrell AT; Saber H; Tang S; Williams G; Jee JM; Liang C; Booth B; Chidambaram N; Morse D; Sridhara R; Garvey P; Justice R; Pazdur R Clin Cancer Res; 2006 Dec; 12(24):7271-8. PubMed ID: 17189398 [TBL] [Abstract][Full Text] [Related]
6. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. Rini BI; Wilding G; Hudes G; Stadler WM; Kim S; Tarazi J; Rosbrook B; Trask PC; Wood L; Dutcher JP J Clin Oncol; 2009 Sep; 27(27):4462-8. PubMed ID: 19652060 [TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Stadler WM; Figlin RA; McDermott DF; Dutcher JP; Knox JJ; Miller WH; Hainsworth JD; Henderson CA; George JR; Hajdenberg J; Kindwall-Keller TL; Ernstoff MS; Drabkin HA; Curti BD; Chu L; Ryan CW; Hotte SJ; Xia C; Cupit L; Bukowski RM; Cancer; 2010 Mar; 116(5):1272-80. PubMed ID: 20082451 [TBL] [Abstract][Full Text] [Related]
8. A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma. Harzstark AL; Small EJ; Weinberg VK; Sun J; Ryan CJ; Lin AM; Fong L; Brocks DR; Rosenberg JE Cancer; 2011 Sep; 117(18):4194-200. PubMed ID: 21387258 [TBL] [Abstract][Full Text] [Related]
17. Clinical results and pharmacokinetics of sorafenib in chronic hemodialysis patients with metastatic renal cell carcinoma in a single center. Kennoki T; Kondo T; Kimata N; Murakami J; Ishimori I; Nakazawa H; Hashimoto Y; Kobayashi H; Iizuka J; Takagi T; Yoshida K; Tanabe K Jpn J Clin Oncol; 2011 May; 41(5):647-55. PubMed ID: 21367805 [TBL] [Abstract][Full Text] [Related]
18. Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma. Procopio G; Verzoni E; Gevorgyan A; Mancin M; Pusceddu S; Catena L; Platania M; Guadalupi V; Martinetti A; Bajetta E Oncology; 2007; 73(3-4):204-9. PubMed ID: 18418013 [TBL] [Abstract][Full Text] [Related]
19. Phase I trial of everolimus plus sorafenib for patients with advanced renal cell cancer. Amato RJ; Flaherty AL; Stepankiw M Clin Genitourin Cancer; 2012 Mar; 10(1):26-31. PubMed ID: 22169794 [TBL] [Abstract][Full Text] [Related]
20. Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group. Townsley CA; Chi K; Ernst DS; Belanger K; Tannock I; Bjarnason GA; Stewart D; Goel R; Ruether JD; Siu LL; Jolivet J; McIntosh L; Seymour L; Moore MJ; J Clin Oncol; 2003 Apr; 21(8):1524-9. PubMed ID: 12697876 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]